124I-CPD-1023-figitumumab

N/A

Report date: 2025/11/20 17:56:58

Base Information

Drug Name124I-CPD-1023-figitumumab

Drug Alias NameIodine-125-CPD-1028125I-CPD-1023-figitumumabI124-FPX-1028Iodine-124-CPD-1028CPD-1028-[125I] +[9]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionApoptosis stimulantsInsulin-like growth factor I receptor modulators

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesFusion Pharma

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharma

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A